
United-Guardian, Inc.
UGNASDAQConsumer DefensiveHousehold & Personal Products
Latest quote
$7.105
+$0.025 · +0.35%
UG company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
77
Undervalued
Momentum
44
Neutral
Sentiment
60
Mixed
Risk resilience
60
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteUnited-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- Headquarters
- US
- CEO
- Donna Vigilante
- Listed since
- Mar 17, 1980
- Employees
- 24
Market position
- Volume
- 9.95K
- 1.41× average
- Average volume
- 7.05K
- Average daily volume
- Market cap
- 32.85M USD
- Beta
- 0.96
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 27.05M USD
- P/E (TTM)
- 13.24×
- P/B (TTM)
- 2.82×
- P/S (TTM)
- 2.93×
- EV / EBITDA
- 9.83×
- Earnings yield
- 7.44%
- Free cash flow yield
- 6.74%
- Dividend yield
- 4.20%
Profitability & efficiency
- Gross margin
- 45.93%
- Operating margin
- 20.82%
- Net margin
- 22.00%
- Return on equity
- 18.75%
- Return on assets
- 16.06%
- Return on invested capital
- 15.62%
Financial health
- Debt / equity
- 0×
- Current ratio
- 7.31×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.55M USD | 12.18M USD | 10.89M USD | 12.7M USD | 13.93M USD |
| Cost of goods sold | 5.51M USD | 5.72M USD | 5.48M USD | 6M USD | 5.75M USD |
| Gross profit | 5.03M USD | 6.46M USD | 5.41M USD | 6.7M USD | 8.18M USD |
| Research and development | 463.64K USD | 456.78K USD | 463.99K USD | 490.77K USD | 478.64K USD |
| Operating expenses | 2.79M USD | 2.81M USD | 2.54M USD | 2.66M USD | 2.51M USD |
| Interest income | 365.31K USD | 434.68K USD | 306.65K USD | 236.7K USD | 233.86K USD |
| Interest expense | — | — | — | 1.62M USD | — |
| Depreciation and amortization | 108.2K USD | 95.89K USD | 105.68K USD | 135.4K USD | 145.98K USD |
| Operating income | 2.24M USD | 3.65M USD | 2.86M USD | 4.04M USD | 5.67M USD |
| Net income | 2.11M USD | 3.25M USD | 2.58M USD | 2.57M USD | 4.66M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- 0.16
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
UG news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$0.60
2025 complete year-23.1% since 2020
2026 partial: $0.30
$0.78
2,020
$1.13
2,021
$0.68
2,022
$0.60
2,024
$0.60
2,025
$0.30
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 28, 2026 | $0.30Semi-Annual | Jul 28, 2026 | Aug 4, 2026 |
Dividend | Jul 25, 2025 | $0.25Semi-Annual | Jul 25, 2025 | Aug 1, 2025 |
Dividend | Feb 10, 2025 | $0.35Semi-Annual | Feb 10, 2025 | Feb 18, 2025 |
Dividend | Jul 23, 2024 | $0.35Semi-Annual | Jul 23, 2024 | Jul 31, 2024 |
Dividend | Feb 9, 2024 | $0.25Semi-Annual | Feb 12, 2024 | Feb 20, 2024 |
Dividend | Jul 25, 2023 | $0.10Semi-Annual | Jul 26, 2023 | Aug 2, 2023 |
Ex-dividend Jul 28, 2026
$0.30
Semi-Annual
Record Jul 28, 2026 · Payment Aug 4, 2026
Ex-dividend Jul 25, 2025
$0.25
Semi-Annual
Record Jul 25, 2025 · Payment Aug 1, 2025
Ex-dividend Feb 10, 2025
$0.35
Semi-Annual
Record Feb 10, 2025 · Payment Feb 18, 2025
Ex-dividend Jul 23, 2024
$0.35
Semi-Annual
Record Jul 23, 2024 · Payment Jul 31, 2024
Ex-dividend Feb 9, 2024
$0.25
Semi-Annual
Record Feb 12, 2024 · Payment Feb 20, 2024
Ex-dividend Jul 25, 2023
$0.10
Semi-Annual
Record Jul 26, 2023 · Payment Aug 2, 2023
UG peers
Continue in GoAI
Research UGresearch.disclaimer











